Cargando…

Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma

Complete en bloc surgical resection offers the best opportunity for the cure of primary retroperitoneal sarcomas (RPS). The potential for disease recurrence, in the form of both loco-regional recurrence and distant metastases, underpins the rationale for postoperative surveillance. There is a paucit...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitaker, John, Nessim, Carolyn, Almond, Max, Ford, Samuel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047263/
https://www.ncbi.nlm.nih.gov/pubmed/36975424
http://dx.doi.org/10.3390/curroncol30030211
_version_ 1785013877106278400
author Whitaker, John
Nessim, Carolyn
Almond, Max
Ford, Samuel J.
author_facet Whitaker, John
Nessim, Carolyn
Almond, Max
Ford, Samuel J.
author_sort Whitaker, John
collection PubMed
description Complete en bloc surgical resection offers the best opportunity for the cure of primary retroperitoneal sarcomas (RPS). The potential for disease recurrence, in the form of both loco-regional recurrence and distant metastases, underpins the rationale for postoperative surveillance. There is a paucity of high-quality evidence underpinning follow-up for RPS patients, and most practice guidelines draw from expert opinion and evidence from soft tissue sarcomas of the extremities. The available observational retrospective data analysis has failed to demonstrate that high-intensity radiological surveillance improves the overall survival in patients. The lack of a robust evidence base has given rise to variations in approaches to post-operative surveillance strategies adopted by specialist centres managing RPS across the world. More high-quality prospective research is needed and planned to more clearly support surveillance approaches that balance oncologic outcomes, patient-centric care, and health service value. Risk stratification tools exist and are available for use in routine practice. Their use will likely support more individualised post-operative surveillance moving forward. Surveillance will likely be underpinned by serial radiological imaging for the medium term. However, developments in genomics offer hope for biomarkers such as ctDNA to impact patient care positively in the future and further support individualised patient care pathways.
format Online
Article
Text
id pubmed-10047263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100472632023-03-29 Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma Whitaker, John Nessim, Carolyn Almond, Max Ford, Samuel J. Curr Oncol Review Complete en bloc surgical resection offers the best opportunity for the cure of primary retroperitoneal sarcomas (RPS). The potential for disease recurrence, in the form of both loco-regional recurrence and distant metastases, underpins the rationale for postoperative surveillance. There is a paucity of high-quality evidence underpinning follow-up for RPS patients, and most practice guidelines draw from expert opinion and evidence from soft tissue sarcomas of the extremities. The available observational retrospective data analysis has failed to demonstrate that high-intensity radiological surveillance improves the overall survival in patients. The lack of a robust evidence base has given rise to variations in approaches to post-operative surveillance strategies adopted by specialist centres managing RPS across the world. More high-quality prospective research is needed and planned to more clearly support surveillance approaches that balance oncologic outcomes, patient-centric care, and health service value. Risk stratification tools exist and are available for use in routine practice. Their use will likely support more individualised post-operative surveillance moving forward. Surveillance will likely be underpinned by serial radiological imaging for the medium term. However, developments in genomics offer hope for biomarkers such as ctDNA to impact patient care positively in the future and further support individualised patient care pathways. MDPI 2023-02-26 /pmc/articles/PMC10047263/ /pubmed/36975424 http://dx.doi.org/10.3390/curroncol30030211 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Whitaker, John
Nessim, Carolyn
Almond, Max
Ford, Samuel J.
Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
title Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
title_full Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
title_fullStr Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
title_full_unstemmed Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
title_short Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
title_sort surveillance post surgery for retroperitoneal soft tissue sarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047263/
https://www.ncbi.nlm.nih.gov/pubmed/36975424
http://dx.doi.org/10.3390/curroncol30030211
work_keys_str_mv AT whitakerjohn surveillancepostsurgeryforretroperitonealsofttissuesarcoma
AT nessimcarolyn surveillancepostsurgeryforretroperitonealsofttissuesarcoma
AT almondmax surveillancepostsurgeryforretroperitonealsofttissuesarcoma
AT fordsamuelj surveillancepostsurgeryforretroperitonealsofttissuesarcoma